The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free ...

Authorities are sealing a private clinic in Thessaloniki after inspectors found it operated an unauthorized oncology unit.

After 3 rounds of chemotherapy, the 59-year-old patient vomited, had diarrhea, and became exhausted. Thinking of the side ...

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist ...

Reeve opens up about a deeply personal health battle he’s been facing for months and shares why he chose to make his journey ...

Flerie AB’s (publ) portfolio company Egetis Therapeutics has received approval from the US Food and Drug Administration (FDA) for EMCITATE® (tiratricol). The drug is expected to become available in ...

HUTCHMED said Tuesday that partner AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for the lung-cancer fighting drugs Orpathys plus T ...

Limited announced that AstraZeneca has submitted a New Drug Application (?NDA?) to the US Food and Drug Administration (?FDA?) for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for the ...

Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting adverse effect of platinum-based chemotherapies that features pain and sensory deficits in the periphery.

Two people could face extradition to the United States after being accused of defrauding health programmes out of millions of ...

FLAURA2 long-term safety data show toxicity peaks during induction with osimertinib plus chemotherapy and declines ...